Telix Pharmaceuticals stock surges by 15% following earnings report. Here’s how Gozellix played a role.

Telix Pharmaceuticals Limited (TLX) saw its stock price surge by nearly 15% on February 20 following the release of its strong 2025 results, optimistic 2026 revenue projections, and the filing of a new shelf registration to support future growth.

In 2025, Telix reported total revenue of approximately $804 million, marking a 56% increase compared to the previous year and falling within its revised forecast range. The company’s fourth-quarter 2025 group revenue reached around $208 million, representing a 46% growth year-over-year driven by the rising demand for Telix’s precision imaging products.

The successful launch of Gozellix, Telix’s second prostate cancer imaging agent in the U.S. played a crucial role in boosting growth. The product benefitted from Medicare reimbursement that began in October 2025. Telix’s Precision Medicine segment generated about $161 million in fourth-quarter revenue, showing a modest increase compared to the previous quarter due to better pricing and product mix despite only a 3% rise in dose volumes.

Looking ahead to 2026, Telix’s management anticipates group revenue to fall within the range of $950 million to $970 million, indicating a mid-teens growth rate compared to 2025. This projection reflects the continued adoption of Illuccix and Gozellix products along with the company’s ongoing efforts in expanding its geographic footprint.

However, despite the revenue growth, Telix’s profitability remains modest. The company reported an operating income of approximately $19 million in 2025, down from $56 million in 2024. The decline can be attributed to significant investments in research and development as well as commercial activities across its therapeutic and manufacturing platforms.

Telix is actively progressing its extensive pipeline, including the submission of a marketing application for TLX101-Px, a brain cancer imaging agent in Europe, and advancing the late-stage development of oncology candidates like TLX591.

From a market perspective, Telix’s stock is currently trading at $7.69, significantly below its 52-week high of $30.36. Analysts have set a mean 12-month target price of $30.84 for TLX stock, indicating considerable upside potential from its current level.

Investors are advised to consider legal challenges brought against Telix, including a securities fraud class action that disputes the accuracy of the company’s claims regarding its prostate cancer therapeutic products and the strength of its supply chain. While the stock has seen a significant decline from previous highs, future performance will be influenced by Telix’s ability to meet its 2026 revenue targets, make progress in its pipeline developments, and resolve legal and financial uncertainties without negatively affecting current shareholders.

In conclusion, Telix Pharmaceuticals Limited has shown promising growth prospects with its robust revenue performance and pipeline advancements. However, investors should remain cautious of legal challenges and expect volatility in the stock price until uncertainties are resolved.